Astrazeneca To Present 19 Abstracts, Including 10 Oral Presentations And Five Late-breaking Presentations, At The European Society Of Cardiology Congress
Portfolio Pulse from Charles Gross
AstraZeneca will present 19 abstracts at the European Society of Cardiology Congress, including data on heart failure management and chronic diseases. Notably, new data from the DELIVER and DAPA-HF trials will assess the efficacy of Forxiga in heart failure patients with deteriorating kidney function.
August 21, 2023 | 9:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's presentation at the ESC Congress, particularly the data on Forxiga's efficacy, could potentially boost investor confidence in the company's leadership in chronic disease management.
The presentation of new data on Forxiga's efficacy in heart failure patients with deteriorating kidney function could potentially enhance AstraZeneca's reputation in chronic disease management. This could lead to increased investor confidence and a potential short-term increase in the company's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100